Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 75

1.

Recurrence-free survival in breast cancer is associated with MRI tumor enhancement dynamics quantified using computer algorithms.

Mazurowski MA, Grimm LJ, Zhang J, Marcom PK, Yoon SC, Kim C, Ghate SV, Johnson KS.

Eur J Radiol. 2015 Jul 18. pii: S0720-048X(15)30055-3. doi: 10.1016/j.ejrad.2015.07.012. [Epub ahead of print]

PMID:
26210095
2.

Medication taking behaviors among breast cancer patients on adjuvant endocrine therapy.

Kimmick G, Edmond SN, Bosworth HB, Peppercorn J, Marcom PK, Blackwell K, Keefe FJ, Shelby RA.

Breast. 2015 Jul 16. pii: S0960-9776(15)00138-1. doi: 10.1016/j.breast.2015.06.010. [Epub ahead of print]

PMID:
26189978
3.

Nuclear basic fibroblast growth factor regulates triple-negative breast cancer chemo-resistance.

Li S, Payne S, Wang F, Claus P, Su Z, Groth J, Geradts J, de Ridder G, Alvarez R, Marcom PK, Pizzo SV, Bachelder RE.

Breast Cancer Res. 2015 Jul 4;17(1):91. doi: 10.1186/s13058-015-0590-3.

4.

Cross-species DNA copy number analyses identifies multiple 1q21-q23 subtype-specific driver genes for breast cancer.

Silva GO, He X, Parker JS, Gatza ML, Carey LA, Hou JP, Moulder SL, Marcom PK, Ma J, Rosen JM, Perou CM.

Breast Cancer Res Treat. 2015 Jul;152(2):347-56. doi: 10.1007/s10549-015-3476-2. Epub 2015 Jun 25.

5.

Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration.

Bossuyt V, Provenzano E, Symmans WF, Boughey JC, Coles C, Curigliano G, Dixon JM, Esserman LJ, Fastner G, Kuehn T, Peintinger F, von Minckwitz G, White J, Yang W, Badve S, Denkert C, MacGrogan G, Penault-Llorca F, Viale G, Cameron D; of the Breast International Group-North American Breast Cancer Group (BIG-NABCG) collaboration; of the Breast International Group-North American Breast Cancer Group BIG-NABCG collaboration.

Ann Oncol. 2015 Jul;26(7):1280-91. doi: 10.1093/annonc/mdv161. Epub 2015 May 27. Review.

PMID:
26019189
6.

Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial).

Ruddy KJ, Guo H, Barry W, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Hudis C, Krop IE, Burstein HJ, Winer EP, Partridge AH, Tolaney SM.

Breast Cancer Res Treat. 2015 Jun;151(3):589-96. doi: 10.1007/s10549-015-3426-z. Epub 2015 May 16.

PMID:
25981899
7.

Breast Cancer Version 2.2015.

Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goetz M, Goldstein LJ, Hudis CA, Isakoff SJ, Marcom PK, Mayer IA, McCormick B, Moran M, Patel SA, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith KL, Smith ML, Soliman H, Somlo G, Telli M, Ward JH, Shead DA, Kumar R.

J Natl Compr Canc Netw. 2015 Apr;13(4):448-75.

PMID:
25870381
8.

Randomized Trial of Telegenetics vs. In-Person Cancer Genetic Counseling: Cost, Patient Satisfaction and Attendance.

Buchanan AH, Datta SK, Skinner CS, Hollowell GP, Beresford HF, Freeland T, Rogers B, Boling J, Marcom PK, Adams MB.

J Genet Couns. 2015 Apr 3. [Epub ahead of print]

PMID:
25833335
9.

Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer.

Aziz H, Marcom PK, Hwang ES.

Ann Surg Oncol. 2015 May;22(5):1404-5. doi: 10.1245/s10434-015-4503-6. Epub 2015 Mar 17. No abstract available.

PMID:
25777094
10.

Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Shapira I, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Guo H, Hudis CA, Krop IE, Burstein HJ, Winer EP.

N Engl J Med. 2015 Jan 8;372(2):134-41. doi: 10.1056/NEJMoa1406281.

11.

Circulating tumor cell analysis in metastatic triple-negative breast cancers.

Magbanua MJ, Carey LA, DeLuca A, Hwang J, Scott JH, Rimawi MF, Mayer EL, Marcom PK, Liu MC, Esteva FJ, Park JW, Rugo HS; Translational Breast Cancer Research Consortium.

Clin Cancer Res. 2015 Mar 1;21(5):1098-105. doi: 10.1158/1078-0432.CCR-14-1948. Epub 2014 Dec 18.

PMID:
25524311
12.

Can breast cancer molecular subtype help to select patients for preoperative MR imaging?

Grimm LJ, Johnson KS, Marcom PK, Baker JA, Soo MS.

Radiology. 2015 Feb;274(2):352-8. doi: 10.1148/radiol.14140594. Epub 2014 Oct 15.

PMID:
25325325
13.

Patient experience and attitudes toward addressing the cost of breast cancer care.

Irwin B, Kimmick G, Altomare I, Marcom PK, Houck K, Zafar SY, Peppercorn J.

Oncologist. 2014 Nov;19(11):1135-40. doi: 10.1634/theoncologist.2014-0117. Epub 2014 Oct 1.

PMID:
25273078
14.

Genetic/familial high-risk assessment: breast and ovarian, version 1.2014.

Daly MB, Pilarski R, Axilbund JE, Buys SS, Crawford B, Friedman S, Garber JE, Horton C, Kaklamani V, Klein C, Kohlmann W, Kurian A, Litton J, Madlensky L, Marcom PK, Merajver SD, Offit K, Pal T, Pasche B, Reiser G, Shannon KM, Swisher E, Voian NC, Weitzel JN, Whelan A, Wiesner GL, Dwyer MA, Kumar R; National comprehensive cancer network.

J Natl Compr Canc Netw. 2014 Sep;12(9):1326-38.

PMID:
25190698
15.

The use of Bayesian hierarchical models for adaptive randomization in biomarker-driven phase II studies.

Barry WT, Perou CM, Marcom PK, Carey LA, Ibrahim JG.

J Biopharm Stat. 2015;25(1):66-88. doi: 10.1080/10543406.2014.919933.

16.

Self-efficacy for coping with symptoms moderates the relationship between physical symptoms and well-being in breast cancer survivors taking adjuvant endocrine therapy.

Shelby RA, Edmond SN, Wren AA, Keefe FJ, Peppercorn JM, Marcom PK, Blackwell KL, Kimmick GG.

Support Care Cancer. 2014 Oct;22(10):2851-9. doi: 10.1007/s00520-014-2269-1. Epub 2014 May 13.

PMID:
24821365
17.

Breast cancer version 3.2014.

Gradishar WJ, Anderson BO, Blair SL, Burstein HJ, Cyr A, Elias AD, Farrar WB, Forero A, Giordano SH, Goldstein LJ, Hayes DF, Hudis CA, Isakoff SJ, Ljung BM, Marcom PK, Mayer IA, McCormick B, Miller RS, Pegram M, Pierce LJ, Reed EC, Salerno KE, Schwartzberg LS, Smith ML, Soliman H, Somlo G, Ward JH, Wolff AC, Zellars R, Shead DA, Kumar R; National Comprehensive Cancer Network Breast Cancer Panel.

J Natl Compr Canc Netw. 2014 Apr;12(4):542-90.

PMID:
24717572
18.

Optimizing the quality of breast cancer biomarker use at Duke Cancer Institute.

Kamal AH, Power S, Broadwater G, Holland AR, Marcom PK.

J Natl Compr Canc Netw. 2014 Feb;12 Suppl 1:S21-4.

19.

Symptom communication in breast cancer: relationships of holding back and self-efficacy for communication to symptoms and adjustment.

Edmond SN, Shelby RA, Kimmick GG, Marcom PK, Peppercorn JM, Keefe FJ.

J Psychosoc Oncol. 2013;31(6):698-711. doi: 10.1080/07347332.2013.835023.

PMID:
24175903
20.

Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer.

Hamilton E, Kimmick G, Hopkins J, Marcom PK, Rocha G, Welch R, Broadwater G, Blackwell K.

Clin Breast Cancer. 2013 Dec;13(6):416-20. doi: 10.1016/j.clbc.2013.08.003. Epub 2013 Oct 4.

PMID:
24099649
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk